PMID- 33840053
OWN - NLM
STAT- MEDLINE
DCOM- 20211130
LR  - 20211130
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Print)
IS  - 1734-1140 (Linking)
VI  - 73
IP  - 6
DP  - 2021 Dec
TI  - Proton pump inhibitor on susceptibility to COVID-19 and its severity: a 
      systematic review and meta-analysis.
PG  - 1642-1649
LID - 10.1007/s43440-021-00263-x [doi]
AB  - BACKGROUND: The negative impacts of proton pump inhibitor (PPI), including the 
      risk of pneumonia and mortality, have been reported previously. This 
      meta-analysis aimed to address the current interest of whether the administration 
      of PPI could increase the susceptibility and risk of poor outcome in COVID-19. 
      METHODS: We performed a systematic literature search from PubMed, Embase, 
      EBSCOhost, and EuropePMC databases up until 3 December 2020. The main outcome was 
      composite poor outcome which comprised of mortality and severe COVID-19. Severe 
      COVID-19 in this study was defined as patients with COVID-19 that fulfill the 
      criteria for severe CAP, including the need for intensive unit care or mechanical 
      ventilation. The secondary outcome was susceptibility, based on cohort comparing 
      COVID-19 positive and COVID-19 negative participants. RESULTS: There were a total 
      of 290,455 patients from 12 studies in this meta-analysis. PPI use was associated 
      with increased composite poor outcome (OR 1.85 [1.13, 3.03], p = 0.014; I(2) 
      90.26%). Meta-regression analysis indicate that the association does not vary by 
      age (OR 0.97 [0.92, 1.02], p = 0.244), male (OR 1.05 [0.99, 1.11], p = 0.091), 
      hypertension (OR 9.98 [0.95, 1.02], p = 0.317), diabetes (OR 0.99 [0.93, 1.05], 
      p = 0.699), chronic kidney disease (OR 1.01 [0.93, 1.10], p = 0.756), 
      non-steroidal anti-inflammatory drug use (OR 1.02 [0.96, 1.09], p = 0.499), and 
      pre-admission/in-hospital PPI use (OR 0.77 [0.26, 2.31], p = 0.644). PPI use was 
      not associated with the susceptibility to COVID-19 (OR 1.56 [0.48, 5.05], 
      p = 0.46; I(2) 99.7%). CONCLUSION: This meta-analysis showed a potential 
      association between PPI use and composite poor outcome, but not susceptibility. 
      PROSPERO ID: CRD42020224286.
CI  - (c) 2021. Maj Institute of Pharmacology Polish Academy of Sciences.
FAU - Pranata, Raymond
AU  - Pranata R
AUID- ORCID: 0000-0003-3998-6551
AD  - Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia.
FAU - Huang, Ian
AU  - Huang I
AUID- ORCID: 0000-0003-1189-8453
AD  - Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia.
AD  - Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, 
      Hasan Sadikin General Hospital, Bandung, Indonesia.
FAU - Lawrensia, Sherly
AU  - Lawrensia S
AD  - Ken Saras General Hospital, Semarang, Indonesia.
FAU - Henrina, Joshua
AU  - Henrina J
AUID- ORCID: 0000-0003-3763-2661
AD  - Balaraja General Hospital, Tangerang, Indonesia.
FAU - Lim, Michael Anthonius
AU  - Lim MA
AUID- ORCID: 0000-0001-7631-6835
AD  - Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia.
FAU - Lukito, Antonia Anna
AU  - Lukito AA
AD  - Department of Cardiology and Vascular Medicine, Siloam Hospitals Lippo Village, 
      Tangerang, Indonesia. Antonia.lukito@uph.edu.
FAU - Kuswardhani, Raden Ayu Tuty
AU  - Kuswardhani RAT
AD  - Department of Internal Medicine, Faculty of Medicine, Udayana University, Sanglah 
      Teaching Hospital, Denpasar- Bali, Indonesia.
FAU - Wibawa, I Dewa Nyoman
AU  - Wibawa IDN
AD  - Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of 
      Medicine, University of Udayana, Denpasar, Indonesia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210411
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - COVID-19/*complications/mortality/physiopathology
MH  - Diabetes Mellitus
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Hypertension
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*adverse effects
MH  - Renal Insufficiency, Chronic
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Severity of Illness Index
PMC - PMC8036156
OTO - NOTNLM
OT  - Coronavirus
OT  - Gastrointestinal
OT  - Infection rate
OT  - Proton pump inhibitor
OT  - Severity
OT  - Susceptibility
COIS- The authors declare that they have no conflict of interest.
EDAT- 2021/04/12 06:00
MHDA- 2021/12/01 06:00
PMCR- 2021/04/11
CRDT- 2021/04/11 20:58
PHST- 2021/01/25 00:00 [received]
PHST- 2021/04/02 00:00 [accepted]
PHST- 2021/03/10 00:00 [revised]
PHST- 2021/04/12 06:00 [pubmed]
PHST- 2021/12/01 06:00 [medline]
PHST- 2021/04/11 20:58 [entrez]
PHST- 2021/04/11 00:00 [pmc-release]
AID - 10.1007/s43440-021-00263-x [pii]
AID - 263 [pii]
AID - 10.1007/s43440-021-00263-x [doi]
PST - ppublish
SO  - Pharmacol Rep. 2021 Dec;73(6):1642-1649. doi: 10.1007/s43440-021-00263-x. Epub 
      2021 Apr 11.